Managing Recurrent Metastatic Head and Neck Cancer
- PMID: 34226077
- DOI: 10.1016/j.hoc.2021.05.009
Managing Recurrent Metastatic Head and Neck Cancer
Abstract
Head and neck squamous cell carcinoma (HNSCC) treatment is often associated with high morbidity especially in the recurrent and/or metastatic (R/M) setting, limiting effective treatment options. Local disease control is important. Therefore, local therapies including reirradiation and salvage surgery, either alone or in combination with systemic treatment, may be used for selected patients with R/M HNSCC. Although chemotherapy and targeted agents have modest efficacy in HNSCC, the advent of immunotherapy has revolutionized the treatment paradigm of R/M HNSCC. Multiple trials have resulted in the past 5 years advocating for its use alone or in combination with chemotherapy.
Keywords: Chemotherapy; Head and neck cancer; Immunotherapy; Metastatic; Recurrent; Systemic therapy; Targeted therapy.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure Dr H. Shaikh and Dr V. Karivedu have no disclosures. Dr T.M. Wise-Draper discloses ownership interest in High Enroll, LLC, Honoraria from Physician Education Resources and research funding from Merck & Co, AstraZeneca/Medimmune, GlaxoSmithKline/Tesaro, Caris Life Sciences, and Bristol-Myers Squibb; he also serves on advisory boards for Shattuck Labs, Exicure, and Rakuten.